Background: Osteonecrosis (ON) is known to be one of the most disabling complications following corticosteroid (CS) medications. However, evidence regarding risk of asymptomatic prevalence
of ON among different diseases and the impact of variable steroid regimens are conflicting. We
aimed to determine the prevalence of ON of femoral head in asymptomatic patients with systemic
rheumatic diseases who received high-dose CS and also clarify its relationship with different dosages
and regimens.
Methods: In this cross-sectional study, 50 consecutive patients receiving high-dose CS for rheumatic
diseases who have no pelvic pain were recruited. MRI of both hips was performed on all patients
using a 1.5 Tesla to diagnose ON.
Results: Of 50 subjects, 18 (36%) developed ON of the femoral head. Groups with and without ON
were comparable in terms of sex, age and mean starting CS dose. There was no statistical difference
in the type of CS regimen including daily dose, peak dose and cumulative dose between the two
groups. However, silent ON was associated with both the cumulative CS dose and the duration of CS
therapy.
Conclusion: According to high prevalence of ON in our selected patients with no other identifiable
risk factor for ON, monitoring of high risk patients with periodic hip MRI would help diagnose necrosis
in early stage.